TARS
Tarsus Pharmaceuticals Inc
73.20$
+1.3%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | -34.1% | -94.4% | -72.7% | +59.5% | +2,734.3% | -100.0% | – | -75.0% | +511.1% | -87.8% | +598.9% | +111.2% | +47.8% | +17.9% | +38.0% | +18.0% | +31.1% | +15.6% | +27.8% | +6.8% | +7.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -43.2% | -91.2% | -136.9% | – | +1,481.8% | -59.6% | +89.6% | -36.3% | +23.9% | +19.3% | +222.5% | +36.0% | +81.6% | +7.9% | +51.9% | +5.8% | +19.7% | +294.3% | -55.6% | -14.0% | +28.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -33.8% | -94.5% | -69.2% | +39.8% | +2,816.0% | -101.4% | – | -76.6% | -114.1% | – | +693.8% | +118.9% | +45.6% | +18.7% | +37.0% | +18.9% | +31.9% | -2.4% | +49.6% | +8.5% | +6.0% | – | |
| – | +0.0% | +0.0% | +250.9% | +0.0% | +0.0% | -49.5% | +74.7% | +116.9% | +14.9% | +360.0% | -5.1% | +114.3% | -55.7% | +41.7% | -21.3% | +50.3% | -20.5% | +13.6% | -8.1% | +23.2% | +1.5% | -3.5% | +9.9% | -9.3% | +2.1% | -1.6% | +39.1% | -14.6% | +8.2% | +4.4% | +10.8% | +23.9% | +38.7% | – | |
| – | +0.0% | +0.0% | +153.0% | +0.0% | +0.0% | -17.6% | +65.4% | +56.6% | +151.8% | +40.9% | +80.9% | +32.6% | +31.7% | -1.8% | +1.5% | +17.3% | +30.6% | +15.6% | +22.0% | +3.2% | +34.3% | +49.6% | +116.6% | -21.5% | +14.0% | -1.5% | +19.2% | +23.1% | +21.2% | +5.5% | +20.3% | +4.4% | +10.5% | – | |
| – | – | – | – | – | – | – | +76.8% | +95.4% | +54.1% | +210.8% | +13.2% | +86.6% | -34.7% | +20.6% | -12.3% | +35.2% | -0.2% | +13.6% | +8.7% | +10.3% | +19.5% | +30.5% | +32.7% | +13.0% | +11.7% | -1.5% | +22.7% | +15.7% | +19.3% | -8.4% | +36.9% | +6.8% | +14.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -32.0% | -315.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | +14.3% | – | – | – | +4,600.0% | -95.2% | -22.2% | +14.3% | +50.0% | +2,533.3% | +72.2% | +16.4% | +9.3% | -1.2% | +19.2% | +5.3% | +15.3% | -0.6% | +114.5% | +9.8% | -6.1% | -4.6% | +1.0% | +1.1% | +4.6% | -3.9% | +1.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -40.4% | -351.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +19,100.0% | +583.3% | – | – | – | -200.0% | – | -90.7% | -1,275.9% | – | -98.1% | +51,800.0% | -101.0% | – | – | – | – | – | -100.9% | – | – | – | – | – | – | – | -214.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -38.8% | -349.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -39.4% | -343.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.